Maha Radhakrishnan appointed as Minovia Therapeutics’ board member

Minovia Therapeutics has announced the appointment of a new board member: Maha Radhakrishnan MD, chief medical officer at Biogen.
The clinical-stage company, which focuses on developing novel Mitochondrial Augmentation Technology (MAT), has appointed Radhakrishnan as the company aims to advance its clinical programmes in primary mitochondrial diseases and haematological disorders associated with mitochondrial dysfunction. Radhakrishnan is currently the chief medical officer at Biogen, and has previously worked as senior vice president and global head of medical, primary business care unit at Sanofi; senior vice president and head of worldwide medical at Bioverativ Therapeutics; and head of Europe and Canada medical and US medical at Biogen. She has previously also worked at Bristol Myers Squibb, Cephalon and United Health Group.
Natalie Yivgi Ohana, co-founder and CEO of Minovia Therapeutics commented: “Mitochondrial diseases are often fatal and currently viewed as untreatable, something we are working relentlessly to change. So far twelve patients suffering Primary Mitochondrial Diseases were dosed with our Mitochondrial Augmentation Technology, both through a compassionate use programme and a phase 1/2 trial in Israel. Minovia invested greatly in research anddevelopmentinthelasttwoyears,establishing strong scientific and GMP foundations, which will enable us to seek approval for Pearson Syndrome and expand to other disease areas. As a board member at Minovia, we will be able to draw on Maha’s considerable medical, regulatory and drug development expertise and experience in bringing successful treatments to patients with primary and secondary mitochondrial diseases.”